company background image
BOT

Botanix PharmaceuticalsASX:BOT Stock Report

Market Cap

AU$61.3m

7D

-1.6%

1Y

-40.0%

Updated

26 Oct, 2021

Data

Company Financials
BOT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BOT Overview

Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Botanix Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.063
52 Week HighAU$0.061
52 Week LowAU$0.19
Beta2.55
1 Month Change-7.35%
3 Month Change-18.18%
1 Year Change-40.00%
3 Year Change-21.25%
5 Year Change46.51%
Change since IPO110.00%

Recent News & Updates

Jul 01
We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Botanix Pharmaceuticals...

Mar 18
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

BOTAU PharmaceuticalsAU Market
7D-1.6%-1.0%0.8%
1Y-40.0%8.7%24.4%

Return vs Industry: BOT underperformed the Australian Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: BOT underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is BOT's price volatile compared to industry and market?
BOT volatility
BOT Beta2.55
Industry Beta1.3
Market Beta1

Stable Share Price: BOT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BOT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19846Vince Ippolitohttps://www.botanixpharma.com

Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. Its product pipeline include BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase Ib clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in North Perth, Australia.

Botanix Pharmaceuticals Fundamentals Summary

How do Botanix Pharmaceuticals's earnings and revenue compare to its market cap?
BOT fundamental statistics
Market CapAU$61.31m
Earnings (TTM)-AU$3.33m
Revenue (TTM)AU$6.89m

8.9x

P/S Ratio

-18.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BOT income statement (TTM)
RevenueAU$6.89m
Cost of RevenueAU$6.57m
Gross ProfitAU$315.80k
ExpensesAU$3.65m
Earnings-AU$3.33m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0034
Gross Margin4.59%
Net Profit Margin-48.41%
Debt/Equity Ratio0%

How did BOT perform over the long term?

See historical performance and comparison

Valuation

Is Botanix Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.95x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BOT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BOT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BOT is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: BOT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BOT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BOT is good value based on its PB Ratio (2.9x) compared to the AU Pharmaceuticals industry average (3.7x).


Future Growth

How is Botanix Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Botanix Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Botanix Pharmaceuticals performed over the past 5 years?

-16.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BOT is currently unprofitable.

Growing Profit Margin: BOT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BOT is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.

Accelerating Growth: Unable to compare BOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: BOT has a negative Return on Equity (-16.03%), as it is currently unprofitable.


Financial Health

How is Botanix Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BOT's short term assets (A$21.6M) exceed its short term liabilities (A$1.0M).

Long Term Liabilities: BOT's short term assets (A$21.6M) exceed its long term liabilities (A$112.2K).


Debt to Equity History and Analysis

Debt Level: BOT is debt free.

Reducing Debt: BOT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BOT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BOT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.5% each year


Dividend

What is Botanix Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BOT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BOT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Vince Ippolito (62 yo)

2.75yrs

Tenure

AU$1,005,207

Compensation

Mr. Vincent P. Ippolito, also known as Vince, serves as the President of Botanix Pharmaceuticals Limited since May 20, 2019 and Executive Chairman since July 18, 2019. Mr. Ippolito is Acting Managing Direc...


CEO Compensation Analysis

Compensation vs Market: Vince's total compensation ($USD754.49K) is above average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Vince's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BOT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: BOT's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Botanix Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Botanix Pharmaceuticals Limited
  • Ticker: BOT
  • Exchange: ASX
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$61.308m
  • Shares outstanding: 973.14m
  • Website: https://www.botanixpharma.com

Number of Employees


Location

  • Botanix Pharmaceuticals Limited
  • 50 Angove Street
  • Level 1
  • North Perth
  • Western Australia
  • 6006
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:29
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.